Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

Lancet (London, England) - 1 Jan 2000

Janssen Harry L A, van Zonneveld Monika, Senturk Hakan, Zeuzem Stefan, Akarca Ulus S, Cakaloglu Yilmaz, Simon Christopher, So Thomas M K, Gerken Guido, de Man Robert A, Niesters Hubert G M, Zondervan Pieter, Hansen Bettina, Schalm Solko W

Abstract excerpt

BACKGROUND: Treatment of HBeAg-positive patients with chronic hepatitis B is not effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and antiviral lamivudine might improve the rate of sustained response. METHODS: 307 HBeAg-positive patients with chronic hepatitis B w...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Double-Blind Method
Share to Drug Carriers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B Surface Antigens

Share to Interferon alpha-2

Share to Lamivudine

Share to Polyethylene Glycols

Source

Identifiers

PMID: 15639293
DOI: 10.1016/S0140-6736(05)17701-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-15639293-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.PMID 15639293Read ↗

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.Semantic proximity Read ↗

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.Semantic proximity Read ↗

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.Semantic proximity Read ↗

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.Semantic proximity Read ↗

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.Semantic proximity Read ↗

Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients.Semantic proximity Read ↗

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)Semantic proximity Read ↗

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.Semantic proximity Read ↗

Chronic hepatitis B virus infection: treatment strategies for the next millennium.Semantic proximity Read ↗

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.Semantic proximity Read ↗

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis BSemantic proximity Read ↗

Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.